Immunovia to host a webcast with the opportunity to learn more about the positive clinical validation of its next-generation pancreatic cancer test

Rhea-AI Summary

Immunovia (IMMNOV), a pancreatic cancer diagnostics company, announced a webcast scheduled for December 17, 2024, at 3 pm CET to discuss the positive clinical validation results of their next-generation pancreatic cancer test, which were published on December 9, 2024.

The webcast will feature presentations from key company executives including CEO Jeff Borcherding, VP Clinical and Medical Affairs Dr. Norma Alonzo Palma, and Laboratory Director Dr. Lisa Ford. Dr. Aimee Lucas, Chief of Gastroenterology & Hepatology at Mount Sinai, will provide additional perspective on the study outcomes.

The company focuses on developing blood-based testing for early pancreatic cancer detection, targeting the US market where an estimated 1.8 million individuals are at high risk and could benefit from annual surveillance testing.

LUND, Sweden, Dec. 16, 2024 /PRNewswire/ -- Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, published positive results in the clinical validation of its next-generation test for pancreatic cancer on December 9, 2024. As a follow up, Immunovia will host a webcast on Tuesday, December 17 at 3 pm CET.

Jeff Borcherding, CEO, Norma Alonzo Palma, PhD, VP Clinical and Medical Affairs and Lisa Ford, PhD, Laboratory Director will present additional details about the results and the implications of the study. Dr. Aimee Lucas, Chief of Gastroenterology & Hepatology at Mount Sinai and Professor of Medicine Icahn School of Medicine, will join the webcast to share perspective on the study outcome. The webcast will be held in English and will offer attendees the opportunity to ask questions. You are welcome to join, see details below.

Link to the webcast: https://link.edgepilot.com/s/e8dd2ee9/T5WEGMPm6EqzxajKwPwQbw?u=https://creo-live.creomediamanager.com/dd81645b-30e0-45e1-af83-75a059fcba71

A recording of the presentation will be available on Immunovia's website.

For more information, please contact:
Karin Almqvist Liwendahl
Chief Financial Officer
karin.almqvist.liwendahl@immunovia.com

Immunovia in brief

Immunovia AB is a diagnostic company whose mission is to increase survival rates for patients with pancreatic cancer through early detection. Immunovia is focused on the development and commercialization of simple blood-based testing to detect proteins and antibodies that indicate a high-risk individual has developed pancreatic cancer.

Immunovia collaborates and engages with healthcare providers, leading experts and patient advocacy groups to make its test available to individuals at increased risk for pancreatic cancer.

USA is the world's largest market for detection of pancreatic cancer. The company estimates that in the USA, 1.8 million individuals are at high-risk for pancreatic cancer and could benefit from annual surveillance testing.

Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For more information, please visit www.immunovia.com

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/immunovia-ab/r/immunovia-to-host-a-webcast-with-the-opportunity-to-learn-more-about-the-positive-clinical-validatio,c4082507

The following files are available for download:

https://mb.cision.com/Main/13121/4082507/3173482.pdf

Press release (PDF)

 

View original content:https://www.prnewswire.com/news-releases/immunovia-to-host-a-webcast-with-the-opportunity-to-learn-more-about-the-positive-clinical-validation-of-its-next-generation-pancreatic-cancer-test-302332369.html

SOURCE Immunovia AB

FAQ

When will Immunovia (IMMNOV) host its webcast on the new pancreatic cancer test results?

Immunovia will host the webcast on Tuesday, December 17, 2024, at 3 pm CET.

What is the market size for Immunovia's (IMMNOV) pancreatic cancer detection test in the USA?

According to the company, 1.8 million individuals in the USA are at high-risk for pancreatic cancer and could benefit from annual surveillance testing.

Who are the key speakers at Immunovia's December 17 webcast?

The key speakers include CEO Jeff Borcherding, VP Clinical and Medical Affairs Dr. Norma Alonzo Palma, Laboratory Director Dr. Lisa Ford, and Dr. Aimee Lucas from Mount Sinai.

When did Immunovia (IMMNOV) publish the clinical validation results for its next-generation pancreatic cancer test?

Immunovia published the positive clinical validation results on December 9, 2024.

What is the main focus of Immunovia's (IMMNOV) diagnostic development?

Immunovia focuses on developing and commercializing simple blood-based testing to detect proteins and antibodies that indicate high-risk for pancreatic cancer.